Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol 150 microgram once-daily versus placebo in COPD
2008-000301-11Phase 3Terminated
- Sponsor
- Novartis
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Indacaterol with Placebo (2 arms). Primary endpoint: 24-hour trough FEV1 after 12 weeks. Started Feb 2008; status: terminated.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-000301-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000301-11.